
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$25.54
−$0.37 · -1.43%
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Previous close
$25.54
−$0.37 · -1.43%
Pre-market
$25.54
$0.00 · 0.00%
Oct 8, 8:29 AM ET
Regular session · ET · Market data may be delayed.
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Day range
Current $25.54
52-week range
Current $25.54
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
83
Deep Value
Sentiment
64
Bullish
Risk
57
Elevated Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Day range
Current $25.54
52-week range
Current $25.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 719.89M USD | 731.97M USD | 644.4M USD | 498.99M USD | 437.77M USD |
| Cost of goods sold | 363.83M USD | 358.11M USD | 293.27M USD | 250.13M USD | 238.03M USD |
| Gross profit | 356.06M USD | 373.86M USD | 351.12M USD | 248.86M USD | 199.74M USD |
| Research and development | 85.84M USD | 73.91M USD | 73.74M USD | 74.77M USD | 60.93M USD |
| Selling, general, and administrative | 129.81M USD | 94.52M USD | 80.39M USD | 66.59M USD | 68.92M USD |
| Operating expenses | 215.65M USD | 168.44M USD | 154.13M USD | 141.36M USD | 129.85M USD |
| Interest income | 8.68M USD | 10.61M USD | 5.46M USD | 1.32M USD | 601K USD |
| Interest expense | 25.48M USD | 30.34M USD | 27.16M USD | 1.85M USD | 885K USD |
| Depreciation and amortization | 63.2M USD | 57.21M USD | 41.78M USD | 28.28M USD | 25.46M USD |
| Operating income | 140.4M USD | 205.42M USD | 196.99M USD | 107.5M USD | 69.89M USD |
| Net income | 98.09M USD | 159.52M USD | 137.55M USD | 91.39M USD | 62.12M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV34.29M0.11%30.86B USD0.25%$119.13-1.11%
Vanguard Morningstar Total Stock Market ETFVTI23.78M0.00%2.3T USD0.03%$381.03-0.40%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV22.31M0.08%26.69B USD0.33%$37.79-1.23%
iShares Russell 2000 ETFIWM21.93M0.03%78.56B USD0.19%$277.7-1.29%
Dimensional - US Targeted Value ETFDFAT13.76M0.05%30B USD0.33%$67.08-1.29%
Vanguard Extended Market ETFVXF8.92M0.01%95.4B USD0.05%$233.49-1.56%
Dimensional - US Small Cap ETFDFAS8.66M0.03%33.66B USD0.31%$77.92-1.38%
State Street SPDR S&P Pharmaceuticals ETFXPH7.82M1.61%462.1M USD0.35%$62.910.00%
Avantis U.S. Small Cap Value ETFAVUV
Vanguard Morningstar Total Stock Market ETFVTI
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
iShares Russell 2000 ETFIWM
Dimensional - US Targeted Value ETFDFAT
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P Pharmaceuticals ETFXPHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.